MTOR and leukemia: Intriguingly, on the functional level we found a clear difference in activity of mTOR signaling with hyperactivation in leukemia cells derived from TTLshort/high-risk patients, which could be effectively targeted by rapamycin resulting in decreased growth, proliferation and successful in vivo treatment.